NCT02808949View on ClinicalTrials.gov

Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

March 3, 2018

Study Completion Date

March 3, 2018

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

Dapivirine

Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.

Trial Locations (1)

35294

Alabama CRS, Birmingham

All Listed Sponsors
lead

International Partnership for Microbicides, Inc.

INDUSTRY

NCT02808949 - Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women | Biotech Hunter | Biotech Hunter